Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03559868 · ClinicalTrials.gov registry record · Phase 1

Inhibition of Sterile Inflammation by Digoxin

A Phase 1 study of Inflammatory Response, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT03559868 is a Phase 1 study of Inflammatory Response that has completed, run by Yale University. The registered enrollment target is 45 participants, below the 175-participant average among 16 other Inflammatory Response trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03559868, a Phase 1 study of Inflammatory Response, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

To investigate the effect of digoxin on pyruvate kinase isoform 2 (PKM2) binding to pro-inflammatory loci and innate immune inflammatory responses in the peripheral blood in healthy subjects.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Digoxin

Study Locations (1)

Connecticut

  • Yale Centre of Clinical Investigation - New Haven

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2021-03-01
Est. Completion 2023-05-05
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT03559868

The ClinicalTrials.gov registry entry for NCT03559868 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 16 other Inflammatory Response trials with a reported enrollment target (74% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Inflammatory Response appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03559868 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT03559868 about?

NCT03559868 is a clinical study titled "Inhibition of Sterile Inflammation by Digoxin". To investigate the effect of digoxin on pyruvate kinase isoform 2 (PKM2) binding to pro-inflammatory loci and innate immune inflammatory responses in the peripheral blood in healthy subjects.

What is the current status of trial NCT03559868?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2021-03-01. Estimated completion is 2023-05-05.

What conditions does trial NCT03559868 study?

This clinical trial studies the following conditions: Inflammatory Response.

What interventions are being tested in trial NCT03559868?

The interventions under investigation include: Placebo (OTHER), Digoxin (DRUG).

Who is sponsoring clinical trial NCT03559868?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03559868 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammatory Response

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.